These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 17631747

  • 21. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
    Devogelaer JP, Geusens P, Daci E, Gielen E, Denhaerynck K, Macdonald K, Hermans C, Vancayzeele S, Abraham I, Boonen S.
    Calcif Tissue Int; 2014 Mar; 94(3):311-8. PubMed ID: 24271562
    [Abstract] [Full Text] [Related]

  • 22. [Paget's disease of bone: diagnosis and treatment].
    Winter EM, Hamdy NA, de Jongh RT, Eekhoff EM, Zillikens MC, Appelman-Dijkstra NM.
    Ned Tijdschr Geneeskd; 2016 Mar; 160():D254. PubMed ID: 27650015
    [Abstract] [Full Text] [Related]

  • 23. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE, Lobaugh B, Lyles KW.
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [Abstract] [Full Text] [Related]

  • 24. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.
    Buckler H, Fraser W, Hosking D, Ryan W, Maricic MJ, Singer F, Davie M, Fogelman I, Birbara CA, Moses AM, Lyles K, Selby P, Richardson P, Seaman J, Zelenakas K, Siris E.
    Bone; 1999 May; 24(5 Suppl):81S-85S. PubMed ID: 10321935
    [No Abstract] [Full Text] [Related]

  • 25. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
    Polyzos SA, Anastasilakis AD, Anagnostis P, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.
    Endokrynol Pol; 2012 May; 63(4):312-5. PubMed ID: 22933168
    [Abstract] [Full Text] [Related]

  • 26. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA, Anastasilakis AD, Litsas I, Efstathiadou Z, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.
    J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
    [Abstract] [Full Text] [Related]

  • 27. Diagnosis and treatment of Paget's disease of bone: a mini-review.
    Ferraz-de-Souza B, Correa PH.
    Arq Bras Endocrinol Metabol; 2013 Nov; 57(8):577-82. PubMed ID: 24343625
    [Abstract] [Full Text] [Related]

  • 28. Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.
    Tucci JR.
    Endocr Pract; 2008 Nov; 14(5):607-10. PubMed ID: 18753106
    [Abstract] [Full Text] [Related]

  • 29. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP, Manicourt DH.
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [Abstract] [Full Text] [Related]

  • 30. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A, Rotés Sala D, Almirall Bernabé M, Carbonell Abelló J.
    Med Clin (Barc); 2006 Oct 28; 127(16):635-6. PubMed ID: 17145033
    [No Abstract] [Full Text] [Related]

  • 31. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Arden-Cordone M, Siris ES, Lyles KW, Knieriem A, Newton RA, Schaffer V, Zelenakas K.
    Calcif Tissue Int; 1997 May 28; 60(5):415-8. PubMed ID: 9115157
    [Abstract] [Full Text] [Related]

  • 32. [Paget's disease: case report].
    Wegierska M, Ignaczak P, Zalewska J, Jeka S.
    Ann Acad Med Stetin; 2011 May 28; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [Abstract] [Full Text] [Related]

  • 33. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
    Polyzos SA.
    Clin Rheumatol; 2011 Jan 28; 30(1):149-50. PubMed ID: 21053036
    [No Abstract] [Full Text] [Related]

  • 34. Active Paget's disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature.
    Gkouva L, Andrikoula M, Kontogeorgakos V, Papachristou DJ, Tsatsoulis A.
    Clin Rheumatol; 2011 Jan 28; 30(1):139-44. PubMed ID: 20886248
    [Abstract] [Full Text] [Related]

  • 35. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Jan 28; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 36. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH.
    Osteoporos Int; 2015 Jul 28; 26(7):1875-91. PubMed ID: 26037791
    [Abstract] [Full Text] [Related]

  • 37. Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.
    Polyzos SA, Kountouras J, Anastasilakis AD, Litsas I, Kita M, Arsos G, Moralidis E, Terpos E.
    Osteoporos Int; 2011 Jan 28; 22(1):363-7. PubMed ID: 20407889
    [Abstract] [Full Text] [Related]

  • 38. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul 28; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 39. Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.
    Reid IR, Sharma S, Kalluru R, Eagleton C.
    Calcif Tissue Int; 2016 Sep 28; 99(3):322-5. PubMed ID: 27193832
    [Abstract] [Full Text] [Related]

  • 40. Pathogenesis and management of Paget's disease of bone.
    Ralston SH, Langston AL, Reid IR.
    Lancet; 2008 Jul 12; 372(9633):155-163. PubMed ID: 18620951
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.